HC Wainwright Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $40.00

Keros Therapeutics (NASDAQ:KROS) had its price target reduced by HC Wainwright from $47.00 to $40.00 in a research note released on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Several other research analysts also recently issued reports on the company. Wells Fargo & Company upped their price objective on Keros Therapeutics from $88.00 to $111.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. William Blair downgraded Keros Therapeutics from an “outperform” rating to a “market perform” rating in a report on Thursday, December 12th. Scotiabank cut their price objective on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research note on Thursday, January 16th. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Finally, Cantor Fitzgerald downgraded shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $42.33.

Keros Therapeutics Trading Up 0.6 %

Shares of NASDAQ KROS opened at $11.01 on Thursday. The stock has a 50-day moving average price of $12.64 and a two-hundred day moving average price of $39.79. Keros Therapeutics has a 12 month low of $9.77 and a 12 month high of $73.00. The company has a market cap of $445.98 million, a price-to-earnings ratio of -2.11 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) EPS for the quarter, beating the consensus estimate of ($1.36) by $0.22. The business had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. On average, sell-side analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Braidwell LP lifted its holdings in shares of Keros Therapeutics by 167.9% in the fourth quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock valued at $29,989,000 after purchasing an additional 1,187,199 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock worth $55,025,000 after buying an additional 577,220 shares in the last quarter. Lynx1 Capital Management LP purchased a new position in shares of Keros Therapeutics in the 4th quarter worth approximately $8,612,000. Millennium Management LLC grew its holdings in shares of Keros Therapeutics by 53.3% in the fourth quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock valued at $13,901,000 after acquiring an additional 305,169 shares in the last quarter. Finally, Alkeon Capital Management LLC increased its position in shares of Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after acquiring an additional 298,694 shares during the last quarter. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.